~~<i id='0D729A182C'><strike id='0D729A182C'><tt id='0D729A182C'><pre id='0D729A182C'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：Wikipedia 2025-10-01 07:42:29 Page View：5

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Search called off for baby washed away in Pennsylvania flash flood
Next article： Peter Hotez and the public health issue of online harassment

comprehensive

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

New lawsuit accuses health insurer Cigna of denying claims in bulk

AnewlawsuitaccusesthehealthinsurerCignaofdenyingclaimsinbulk.JuliaRendleman/GettyImagesforEventiveMa

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Pfizer plans to depart BIO

Pfizerplanstoexitamajorbiotechnologyindustrytradeassociation.CindyOrd/GettyImagesforPfizer/BioNTechW